The European Medicines Agency (EMA) is set to discuss extending the application of Novo Nordisk A/S’s NVO weight loss drug, Wegovy (semaglutide), to include the reduction of stroke and heart attack risks.
This move, stemming from the SELECT trial, is anticipated to enhance the Danish pharmaceutical company’s argument for integrating Wegovy into public health systems across Europe.
The EMA’s drug assessment panel will scrutinize the potential new usage during its monthly meeting scheduled for 22-25 January 2024.
The SELECT trial findings from last year indicated that Wegovy exhibited a lower cardiovascular risk in obese participants.
The trial achieved its primary objective by demonstrating a statistically significant and superior reduction in MACE of 20% for people treated with semaglutide 2.4 mg compared to placebo.
A comprehensive U.S. study revealed that the use of Novo Nordisk drugs Ozempic and Wegovy, widely prescribed for type 2 diabetes and obesity, respectively, is not associated with an increased risk of suicidal thoughts.
Earlier this month, Lars Fruergaard Jorgensen, CEO of Novo Nordisk, shared insights during the JPMorgan Healthcare conference, highlighting Wegovy’s efficacy for weight loss, indicating that patients are likely to continue with Wegovy for more extended periods compared to older treatments commonly used.
Read Next: Pfizer’s Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles.
Price Action: NVO shares are down 1.12% at $105.76 on the last check Monday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
